公开(公告)号：US20230364185A1

公开(公告)日：2023-11-16

申请号：US18185443

申请日：2023-03-17

申请人： Allgenesis Biotherapeutics Inc.

发明人： Tan Nguyen ,  Pei-Tzu WU ,  Yung-Sheng Chang ,  Madhu Cherukury

IPC分类号： A61K38/17 ,  A61K47/10 ,  A61K47/26 ,  A61K47/18 ,  C07K14/71 ,  A61K9/08 ,  C07K14/705 ,  A61K47/12 ,  A61K9/00 ,  C07K19/00 ,  A61K47/02

CPC分类号： A61K38/179 ,  A61K47/10 ,  A61K38/1777 ,  A61K47/26 ,  A61K47/183 ,  C07K14/71 ,  A61K9/08 ,  C07K14/70546 ,  A61K47/12 ,  A61K9/0048 ,  A61K9/0019 ,  C07K19/00 ,  A61K47/02 ,  C07K2319/30

摘要： The present invention relates to a biologic that inhibits angiogenesis. In particular, the present invention relates to fusion proteins that inhibit the integrin activated pathway and one other angiogenic factor-activated pathway as well as formulation compositions of such fusion proteins, as well as methods for producing and using the same.

公开(公告)号：US20170369552A1

公开(公告)日：2017-12-28

申请号：US15542692

申请日：2016-03-10

申请人： Allgenesis Biotherapeutics Inc. ,  AP Biosciences, Inc.

发明人： Kevin ZEN ,  Pei-Tzu WU ,  Jeng-Horng HER ,  Huang-Tsu CHEN ,  Jiun-Shyang LEOU ,  Ching-Hsuan HSU

IPC分类号： C07K14/71 ,  A61K38/00

CPC分类号： C07K14/71 ,  A61K38/00 ,  C07K2319/30 ,  C07K2319/70

摘要： Fusion proteins containing a PDGF binding portion, a VEGF binding portion, and an Fc antibody region are described. Also described are nucleic acids encoding the fusion proteins, compositions comprising the fusion proteins, and methods of using the fusion proteins for treating or preventing clinical conditions characterized by abnormal angiogenesis, such as vascular permeability, edema or inflammation.

公开(公告)号：US20190194271A1

公开(公告)日：2019-06-27

申请号：US16282786

申请日：2019-02-22

申请人： ALLGENESIS BIOTHERAPEUTICS INC.

发明人： Pei-Tzu WU ,  Jia-Hau SHIU ,  Madhu CHERUKURY ,  Tan NGUYEN ,  Kevin Zen

IPC分类号： C07K14/46 ,  C07K14/71 ,  A61P9/10 ,  A61K38/00

CPC分类号： C07K14/46 ,  A61K38/00 ,  A61P9/10 ,  C07K14/71 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/30

摘要： The present invention relates to a biologic that inhibits angiogenesis. In particular, the present invention relates to fusion proteins that inhibit the integrin activated pathway and one other angiogenic factor-activated pathway, the compositions of these fusion proteins, as well as methods for producing and using the same.

公开(公告)号：US20180170979A1

公开(公告)日：2018-06-21

申请号：US15739089

申请日：2016-06-24

申请人： ALLGENESIS BIOTHERAPEUTICS INC.

发明人： Pei-Tzu WU ,  Jia-Hau SHIU ,  Madhu CHERUKURY ,  Tan NGUYEN ,  Kevin ZEN

IPC分类号： C07K14/46 ,  A61P9/10 ,  C07K14/71

CPC分类号： C07K14/46 ,  A61K38/00 ,  A61P9/10 ,  C07K14/71 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/30

摘要： The present invention relates to a biologic that inhibits angiogenesis. In particular, the present invention relates to fusion proteins that inhibit the integrin activated pathway and one other angiogenic factor-activated pathway, the compositions of these fusion proteins, as well as methods for producing and using the same.